Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure

Sponsor
Mansoura University
Study ID
NCT06783166
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Acute Heart Failure

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10mg — DRUG
    Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
  • Acetazolamide 500mg — DRUG
    Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.

Study Details

This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.

Key Dates

Start date
Aug 15, 2024
Status verified
Jan 2025
Primary completion
Jul 1, 2025
Completion
Aug 1, 2025

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin 10mg
    Patients will receive once daily dapagliflozin 10 mg orally in addition to loop diuretic therapy and standard care for 3 days.
  • Active Comparator: Acetazolamide 500mg
    Patients will receive once daily acetazolamide 500 mg orally in addition to loop diuretic therapy and standard care for 3 days.

Primary Outcome Measure

Change in dyspnea VAS (Visual analogue scale) [ Time Frame: From baseline to day 3 ]

Central Contacts

Related Studies